Abgenix Inc (1052837) SEC Filing 10-Q Quarterly report for the period ending Thursday, March 31, 2005

Abgenix Inc

CIK: 1052837

Exhibit 99.1



Contact:                                                   Ami Knoefler

Senior Director

Corporate Communications and Investor Relations

510-284-6350 or 510-284-6605




FREMONT, Calif., April 26, 2005 - Abgenix, Inc. (Nasdaq:ABGX) today reported financial results for the first quarter ended March 31, 2005.


For the quarter ended March 31, 2005, the company reported a net loss of $42.6 million, or $0.48 per share, compared to a net loss of $41.6 million or $0.47 per share for the same period in 2004.  Net cash used in operating activities in the first quarter of 2005 was $15.2 million.  The company ended the quarter with $400.7 million in cash, cash equivalents and marketable securities.


“In the first quarter of 2005, we continued to focus on preparing for the potential BLA submission for panitumumab.  We have contained overall costs by offsetting our increasing spend on panitumumab with cost reductions in other areas of the company,” said Bill Ringo, president and CEO of Abgenix.


Revenues for the first quarter of 2005 were $2.7 million, compared to $2.9 million for the same period in 2004.  Contract revenues for the quarter ended March 31, 2005 primarily consisted of milestones and fees from technology licensing agreements, including a milestone from Amgen for advancing a XenoMouse®-derived fully human antibody into the clinic.  The company’s revenues typically result from milestone payments and fees associated with various collaborations and technology licensing agreements.


Operating expenses for the first quarter of 2005 were $44.9 million, compared to $44.5 million for the same period in 2004.  The majority of first quarter 2005 research and development costs related to advancement of the company’s proprietary clinical product candidates, including its lead oncology product candidate, panitumumab, and ABX-PTH, a fully human antibody for the potential treatment of secondary hyperparathyroidism (SHPT).  Included in both periods were manufacturing start-up costs related to the company’s antibody production facility.  A portion of the costs associated with this facility will continue to be classified as manufacturing start-up costs until the facility is operating at normal capacity.





The following information was filed by Abgenix Inc on Tuesday, April 26, 2005 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Abgenix Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Abgenix Inc.


Assess how Abgenix Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Abgenix Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2005 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
CIK: 1052837
Form Type: 10-Q Quarterly Report
Accession Number: 0001104659-05-022100
Submitted to the SEC: Tue May 10 2005 3:00:36 PM EST
Accepted by the SEC: Tue May 10 2005
Period: Thursday, March 31, 2005
Industry: Biological Products No Disgnostic Substances

External Resources:

Bookmark the Permalink: